Adaptive Platform Treatment Trial for Outpatients with COVID-19 - ACTIV-2
Enrolling By Invitation
18 years - 100 years
All
Phase
2
20 participants needed
1 Location
Brief description of study
The ACTIV-2 Study is testing an investigational medicine to see if they are safe and can help adults with COVID-19 get better.
The type of investigational medicine you might receive in the study is a monoclonal antibody. Antibodies are naturally made by your body to help fight disease. Monoclonal antibodies are made in the laboratory and help your body attack invaders, such as viruses, to keep them from entering your cells.
We also want to see if this study drug is safe, can stop the disease process and prevent hospitalization.
If you decide to join, you would be given information about the medicines currently being tested.
Detailed description of study
The study lasts about 6 months. You will have in-person visits to check on the status of your health. Most of these visits will happen during the first month of the study. You will also have phone calls or video chats from your home with a researcher.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: COVID-19,covid19
-
Age: 18 years - 100 years
-
Gender: All
To join, you must be:
•
18
years or older
•
Have
tested positive for COVID-19 within the past 7 days
•
Experiencing
one of the following:
§ Fever
§ Cough
§ Shortness of Breath
§ Sore Throat
§ Body Pain
§ Fatigue
§ Headache
Updated on
04 Aug 2024.
Study ID: 843864
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
